Search research articles
Contact Us
Filters
Showing results (241-250 of 256) with videos related to
Page
of 26
Sort By:
Cancer Research
|
October 12, 2010
Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis
Victoria A Brown, Ketan R Patel, Maria Viskaduraki, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 12, 2005
Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials
J Drevs, U Zirrgiebel, C I M Schmidt-Gersbach, et al.
International Journal of Cancer
|
September 15, 2010
Curcumin ameliorates oxaliplatin-induced chemoresistance in HCT116 colorectal cancer cells in vitro and in vivo
Lynne M Howells, Stewart Sale, Sathya Neelature Sriramareddy, et al.
The Journal of Nutrition
|
May 28, 2019
Curcumin Combined with FOLFOX Chemotherapy Is Safe and Tolerable in Patients with Metastatic Colorectal Cancer in a Randomized Phase IIa Trial
Lynne M Howells, Chinenye O O Iwuji, Glen R B Irving, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 13, 2001
Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer
N C Levitt, F A Eskens, K J O'Byrne, et al.
Cancer Research
|
September 16, 2010
Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients
Ketan R Patel, Victoria A Brown, Donald J L Jones, et al.
British Journal of Cancer
|
February 14, 2018
A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma
Natalie Cook, Bristi Basu, Donna-Michelle Smith, et al.
Cancer Prevention Research (Philadelphia, Pa.)
|
December 13, 2012
Prolonged biologically active colonic tissue levels of curcumin achieved after oral administration--a clinical pilot study including assessment of patient acceptability
Glen R B Irving, Lynne M Howells, Stewart Sale, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 1, 2003
Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies
Bruno Morgan, Anne L Thomas, Joachim Drevs, et al.
Cancer Letters
|
May 17, 2015
Curcumin inhibits cancer stem cell phenotypes in ex vivo models of colorectal liver metastases, and is clinically safe and tolerable in combination with FOLFOX chemotherapy
Mark I James, Chinenye Iwuji, Glen Irving, et al.
Page
of 26
Search research articles
Search
Showing results (241-250 of 256) with videos related to
Sort By:
Page
of 26
Cancer Research
|
October 12, 2010
Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis
Victoria A Brown, Ketan R Patel, Maria Viskaduraki, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 12, 2005
Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials
J Drevs, U Zirrgiebel, C I M Schmidt-Gersbach, et al.
International Journal of Cancer
|
September 15, 2010
Curcumin ameliorates oxaliplatin-induced chemoresistance in HCT116 colorectal cancer cells in vitro and in vivo
Lynne M Howells, Stewart Sale, Sathya Neelature Sriramareddy, et al.
The Journal of Nutrition
|
May 28, 2019
Curcumin Combined with FOLFOX Chemotherapy Is Safe and Tolerable in Patients with Metastatic Colorectal Cancer in a Randomized Phase IIa Trial
Lynne M Howells, Chinenye O O Iwuji, Glen R B Irving, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 13, 2001
Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer
N C Levitt, F A Eskens, K J O'Byrne, et al.
Cancer Research
|
September 16, 2010
Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients
Ketan R Patel, Victoria A Brown, Donald J L Jones, et al.
British Journal of Cancer
|
February 14, 2018
A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma
Natalie Cook, Bristi Basu, Donna-Michelle Smith, et al.
Cancer Prevention Research (Philadelphia, Pa.)
|
December 13, 2012
Prolonged biologically active colonic tissue levels of curcumin achieved after oral administration--a clinical pilot study including assessment of patient acceptability
Glen R B Irving, Lynne M Howells, Stewart Sale, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 1, 2003
Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies
Bruno Morgan, Anne L Thomas, Joachim Drevs, et al.
Cancer Letters
|
May 17, 2015
Curcumin inhibits cancer stem cell phenotypes in ex vivo models of colorectal liver metastases, and is clinically safe and tolerable in combination with FOLFOX chemotherapy
Mark I James, Chinenye Iwuji, Glen Irving, et al.
Page
of 26